EUVIMEDEUVIMED entdecken
Vergleichsstudie

Parathyroid hormone levels following denosumab vs. zoledronic acid therapy for osteoporosis

Pnina Rotman-Pikielny, Liat Barzilai-Yosef, Erez Ramaty, Sofia Braginski-Shapira, Michal Kasher Meron, Tzipi Hornik Lurie

Bone · 2025

DOI: 10.1016/j.bone.2025.117407 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Bone, 2025. Verfasst von Pnina Rotman-Pikielny und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Endocrinology, Diabetes and Metabolism, Meir Medical Center, Kfar Saba, Israel; Faculty of Medical & Health Sciences, Tel Aviv Universit…. Hauptthemen laut MEDLINE: Parathyroid Hormone, Denosumab, Osteoporosis, Imidazoles. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Parathyroid HormoneDenosumabOsteoporosisImidazolesDiphosphonatesBone Density Conservation AgentsHumansZoledronic AcidFemaleAgedMiddle AgedRetrospective StudiesAged, 80 and over

Stichwörter der Autor:innen

Bone density conservation agentsDenosumabOsteoporosisParathyroid hormonePost-menopausal osteoporosisSecondary hyperparathyroidismZoledronic acid

Substanzen

Zoledronic AcidParathyroid HormoneDenosumabImidazolesDiphosphonatesBone Density Conservation Agents

Autor:innen und Institutionen

  • Institute of Endocrinology, Diabetes and Metabolism, Meir Medical Center, Kfar Saba, Israel; Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv, Israel. Electronic address: pnina.rotman@clalit.org.il.
  • Institute of Endocrinology, Diabetes and Metabolism, Meir Medical Center, Kfar Saba, Israel.
  • Institute of Endocrinology, Diabetes and Metabolism, Meir Medical Center, Kfar Saba, Israel; Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv, Israel.
  • Research Institute, Meir Medical Center, Kfar Saba, Israel.

Zitieren

APA

Rotman-Pikielny, P., Barzilai-Yosef, L., Ramaty, E., Braginski-Shapira, S., Meron, M. K., & Lurie, T. H. (2025). Parathyroid hormone levels following denosumab vs. zoledronic acid therapy for osteoporosis. Bone. https://doi.org/10.1016/j.bone.2025.117407

Vancouver

Rotman-Pikielny P, Barzilai-Yosef L, Ramaty E, Braginski-Shapira S, Meron MK, Lurie TH. Parathyroid hormone levels following denosumab vs. zoledronic acid therapy for osteoporosis. Bone. 2025. doi:10.1016/j.bone.2025.117407

BibTeX
@article{RotmanPikielny2025,
  author = {Rotman-Pikielny, Pnina and Barzilai-Yosef, Liat and Ramaty, Erez and Braginski-Shapira, Sofia and Meron, Michal Kasher and Lurie, Tzipi Hornik},
  title = {Parathyroid hormone levels following denosumab vs. zoledronic acid therapy for osteoporosis},
  journal = {Bone},
  year = {2025},
  doi = {10.1016/j.bone.2025.117407}
}
Kostenlos starten →